Pharmaceutical News and Articles

Breast Cancer Screening In Women's 40s Can Save Lives, Study Says

TUESDAY, June 3, 2025 Starting breast cancer screening in women s early 40s will save more lives, a new study argues.Nearly 3 in 4 women (73 ) in their 40s find

Vape Package Warnings Can Deter Use, But Current Rules Are Lacking

TUESDAY, June 3, 2025 Warning labels placed on e-cigarettes can effectively discourage vaping, but the warning now required in the U.S. could be better, a new e

More Seniors Are Regular Weed Users

TUESDAY, June 3, 2025 Add weed use to goofy jokes, outdated clothes, old music and other things Grandpa and Grandma enjoy that could potentially embarrass their

Self-Employment Is Good For Heart Health, Especially For Women

TUESDAY, June 3, 2025 Being your own boss might seem potentially stressful, but self-employed women appear to have better heart health than those toiling for a

How Can A Daily Cup Of Beans Improve Your Health?

TUESDAY, June 3, 2025 Beans aren t just the musical fruit, they can be pure magic for your health, a new study says.Eating a daily cup of beans significantly im

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial

Merck (NYSE MRK), known as MSD outside of the United States and Canada, today announced results from the dose confirmation portion of the Phase 2 3 waveLINE-003

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

NEW HAVEN, Conn. and NEW YORK, May 31, 2025 Arvinas, Inc. (Nasdaq ARVN) and Pfizer Inc. (NYSE PFE) today announced detailed results from the Phase 3 VERITAC-2 c

Johnson & Johnson Unveils First-in-Human Results for Pasritamig, Showing Early Anti-Tumor Activity in Prostate Cancer

CHICAGO, JUNE 1, 2025 Johnson Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody t

Elinzanetant Significantly Reduces Frequency of Moderate to Severe Vasomotor Symptoms Associated with Endocrine Therapy for Breast Cancer in Phase III OASIS-4 Study

Berlin, June 2, 2025 Detailed results from the Phase III OASIS-4 study found that the investigational compound elinzanetant showed a statistically significant r